TDC
TOVX icon

Thompson Davis & Co’s Theriva Biologics TOVX Stock Holding History

Thompson Davis & Co’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2
Closed -$46K – 1164
2015
Q4 		$46K Hold
2
– – 0.06% 273
2015
Q3 		$45K Hold
2
– – 0.06% 282
2015
Q2 		$57K Hold
2
– – 0.07% 283
2015
Q1 		$44K Hold
2
– – 0.05% 317
2014
Q4 		$29K Hold
2
– – 0.03% 416
2014
Q3 		$36K Hold
2
– – 0.05% 339
2014
Q2 		$34K Hold
2
– – 0.05% 308
2014
Q1 		$51K Hold
2
– – 0.08% 242
2013
Q4 		$31K Buy
+2
New +$25.2K 0.05% 298

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Thompson Davis & Co's TOVX Position: Q1 2016 in Review

Thompson Davis & Co sold out of Theriva Biologics (TOVX) in Q1 2016, closing a stake of 2 shares — an estimated $46K sold.

Thompson Davis & Co first reported a position in TOVX in Q4 2013 and held it in 9 quarters. The position peaked at $57K in Q2 2015. 56 funds tracked by Wall St. Rank hold TOVX as of Q1 2016.

  • Thompson Davis & Co reported no remaining Theriva Biologics position as of Q1 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 2 Theriva Biologics shares in Q1 2016, an estimated $46K.
  • Thompson Davis & Co first reported a position in Theriva Biologics in Q4 2013 and held it in 9 quarters.
  • Thompson Davis & Co's Theriva Biologics position peaked at $57K in Q2 2015.
  • 56 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2016.

Based on Thompson Davis & Co's 13F filing for Q1 2016, filed 2 May 2016.